Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMP-2 siRNA
- Development stage
- Preclinical
- Lead developer
- Santa Cruz Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
MMP-2 siRNA is a small interfering RNA (siRNA) research compound designed to silence or knock down the expression of Matrix Metalloproteinase-2 (MMP-2), also known as gelatinase A. MMP-2 is a zinc-dependent proteolytic endopeptidase that plays a critical role in extracellular matrix remodeling, tumor invasion, and metastasis. By utilizing the RNA interference (RNAi) pathway, MMP-2 siRNA mediates the sequence-specific degradation of MMP-2 mRNA, thereby reducing the levels of the functional enzyme. Preclinical research has investigated the use of MMP-2 siRNA in various disease contexts, including glioblastoma, prostate cancer, hepatic fibrosis, and cardiac ischemia/reperfusion injury. It is primarily available as a research-use-only (RUO) reagent from suppliers such as Santa Cruz Biotechnology.
- Other names
- Matrix Metalloproteinase-2 siRNAgelatinase A siRNAMMP2 siRNAMMP-2 siRNAMMP 2 siRNA
02
Targets
MMP2 (Matrix metalloproteinase-2)
Beyond the preview
Go deeper on MMP-2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMP-2 siRNA.